These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12590034)

  • 1. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
    Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
    J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
    Cömlekçi A; Biberoglu S; Hekimsoy Z; Okan I; Pişkin O; Sekeroglu B; Alakavuklar M
    Intern Med; 1998 Apr; 37(4):396-7. PubMed ID: 9630201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
    Mishra A; Wong L; Jonklaas J
    Endocrine; 2001 Mar; 14(2):159-64. PubMed ID: 11394632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
    Sims EC; Rogers PB; Besser GM; Plowman PN
    Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone metastases and tumor-induced hypercalcemia.
    Body JJ
    Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pamidronate, hypocalcemia, and calcium and vitamin D supplementation.
    Altundag O; Altundag K
    J Clin Oncol; 2004 May; 22(10):2035; author reply 2035. PubMed ID: 15143101
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
    Kim S
    J Oncol Pharm Pract; 2019 Oct; 25(7):1787-1793. PubMed ID: 30419769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pamidronate-induced irreversible symptomatic hypocalcemia in a dog with hypercalcemia after glucocorticoid withdrawal: a case report.
    Oh YI; An JH; Lim GH; Park SM; Kim TH; Seo KW; Youn HY
    BMC Vet Res; 2024 May; 20(1):227. PubMed ID: 38790012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level.
    Epperla N; Pathak R
    WMJ; 2015 Aug; 114(4):163-6; quiz 167. PubMed ID: 26436186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose intravenous pamidronate for metastatic bone pain.
    Purohit OP; Anthony C; Radstone CR; Owen J; Coleman RE
    Br J Cancer; 1994 Sep; 70(3):554-8. PubMed ID: 8080746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.
    Maalouf NM; Heller HJ; Odvina CV; Kim PJ; Sakhaee K
    Endocr Pract; 2006; 12(1):48-53. PubMed ID: 16524863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
    De Schepper J; de Pont S; Smitz J; De Coster D; Schots R; Otten J
    Eur J Pediatr; 1999 Sep; 158(9):765-6. PubMed ID: 10485313
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of long-term administration of bisphosphonates in elderly cancer patients.
    Tralongo P; Repetto L; Di Mari A; Mauceri G; Bollina R; Ferrau' F; Conti G
    Oncology; 2004; 67(2):112-6. PubMed ID: 15539914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
    Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients.
    Chong G; Hoang T; Davis ID
    Aust N Z J Med; 1999 Feb; 29(1):96-7. PubMed ID: 10200826
    [No Abstract]   [Full Text] [Related]  

  • 18. Electrolyte abnormalities with zoledronic acid therapy.
    Sorscher SM
    Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
    [No Abstract]   [Full Text] [Related]  

  • 19. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
    Conte PF; Latreille J; Mauriac L; Calabresi F; Santos R; Campos D; Bonneterre J; Francini G; Ford JM
    J Clin Oncol; 1996 Sep; 14(9):2552-9. PubMed ID: 8823335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor.
    Hanamura M; Iwamoto T; Soga N; Sugimura Y; Okuda M
    Biol Pharm Bull; 2010; 33(4):721-4. PubMed ID: 20410614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.